Cardiovascular Prevention
11
4
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Randomized, Double-blind Crossover Trial Comparing Low-GI Functional vs. Standard Wholegrain Carbohydrates on Glycolipid Metabolism and Vascular Stress Markers in Adults With Suboptimal Triglyceridemia
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
Implementing Shared Decision Making (SDM) For Individualized CV Prevention (SDM4IP)
Connect2Move: Valorization of Natural Cardio Trekking Hiking Trails
The YOU-Fish Study: Fish and Omega 3 Supplementation in Young Adults
The Cardiovascular Prevention Program
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
New Cardiovascular Risk Screening Strategy.
Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness
Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy